MGMT and central nervous system cancer: Epigenetic changes are another obstacle in cancer therapy; for example, in patients with gliomas, methylation of the promoter of the DNA-repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) is a problem in cancer therapy with alkylating agents [139] (Table 2).